
    
      A 52-week, double-blind, randomised, multi-centre, parallel-group, Phase III study in
      patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort®
      (budesonide/formoterol) Turbuhaler® 160/4.5 μg 'as needed' compared with terbutaline
      Turbuhaler® 0.4 mg 'as needed' and with Pulmicort® (budesonide) Turbuhaler® 200 μg twice
      daily plus terbutaline Turbuhaler® 0.4 mg 'as needed'
    
  